Published Date: 19/01/2009
Category: Drug Delivery & Devices
Research Report Decription
This report gives in depth analysis of innovative drug delivery
technologies that are being applied to the delivery of biopharmaceuticals. It discusses the key challenges and opportunities which players face in the development and delivery of macromolecule drugs both in the near- and long-term and encompasses different strategies for systemic delivery and novel approaches for alternative routes of delivery.
Key Questions Answered:
- Which companies and academic institutes are actively involved in biopharmaceutical research?
- What are the key areas of therapeutic focus for biotherapeutics in the near- and long-term?
- What are the key obstacles companies and delivery technologist need to overcome to commercialize biotherapeutics?
- How will the delivery technologies drive the development of innovative biological agents in the future?
- Which delivery technologies and platforms are likely to win in the near-term and the long-term, and why?
- Where are the market opportunities now and in the future?
- What do we predict will be the value of the biotherapeutics by 2015 and 2020?
Companies Mentioned:
Abbott
Laboratories, Acambis, Access Pharmaceuticals, Acusphere, Advanced BioScience
Laboratories, Aegis Therapeutics, Affymax, Alkermes, ALZA Corporation, Amgen,
Amylin, Aphios, Aradigm, Arius Research, AS Biotech AG, AstraZeneca, Aurigene,
AVRA Labs, Bayer Schering, Bioceuticals, Biocon, Biogen Idec, BioGeneriX AG,
BioPartners, BioSante Pharmaceuticals, Bristol-Myers Squibb, Calando
Pharmaceuticals, Camurus, Cangene Corporation, Cenotcor, Chugai, CoGenesys,
Controlled Therapeutics, CT Arzneimittel, Dr. Reddy's, Dragon Pharmaceuticals, Eisai,
Elan Pharmaceuticals, Eli Lilly & Company, Emisphere Technologies, Enzon
Pharmaceuticals, Flamel Technologies, GeneMedix, Genentech, Generex
Biotechnology Corporation, Genzyme, GlaxoSmithKline, Glide Pharma, GVK Bio,
Hospira, ImClone, Inovio Biomedical Corporation, Intercell AG, Iomai
Corporation, Johnson & Johnson, Kirin, Lonza, MacroGenics, MDRNA (formerly
Nastech Pharmaceuticals), MedImmune (acquired by AstraZeneca), Medincell S.A.,
Merck Serono, Mirus Bio Corporation (acquired by Roche), Modigene, Momenta Pharmaceuticals,
Nanotechnology Victoria Ltd, Neose Technologies, Novartis, Novo Nordisk,
Novopharm, OctoPlus NV, Serenex, SGX Pharmaceuticals, Shasun Chemicals,
Shionogi, Shire Pharmaceuticals, Sirtris Pharmaceuticals, Stada, Arzneimittel
AG, Syngene, Talceris, Tanabe, Teva Pharmaceutical Industries Ltd, TheraJect,
Titan Pharmaceuticals, TransPharma, UCB, VGX, Pharmaceuticals, Vyteris,
Wockhardt, Wyeth, Zenyaku Kogyu
Paper Highlights:
- The biopharmaceutical market is estimated to be worth around $79 billion in 2007 growing by 15% per annum, focusing on two key areas, monoclonal antibodies ($27 billion) and biological active proteins ($52 billion) and driven by improvements in manufacturing technologies and advances in biotechnology and drug delivery platforms.
- Most biopharmaceutical products, being large molecules, have hitherto been given by injection. Companies have focused on new technologies to optimize injectable delivery such as needle freedevices, sustained/controlled release and long-acting subcutaneous implants. However, alternative routes of delivery are now being explored including transdermal drug delivery systems, (iontophoresis, micro needlearray, electroporation), pulmonary delivery, oral delivery, nasal delivery and nanotechnology platforms.
- The generic sector of the pharmaceuticalmarket has been evolving to keep abreast with changing market conditions, and a growing interest in developing biopharmaceuticals. Several leading biopharmaceutical companies generate sales in excess of US$1 billion per annum which has attracted the attention of generic specialists who are now embarking on the development of generic copies of biopharm products, referred to as “biosimilars".The expertise required to choose, design, execute and monitor biopharmaceutical production processes is radically different from that involved in synthetic drug production and is the province of molecular biologists rather than pharmaceutical chemists. This has resulted in rapid advances in manufacturing processes and increased the need for outsourcing to access specialist technologies.
- The advent of medicines tailored to individual genotypes is brought a significant step closer by the link between genetic profiling and biopharm products with highly specific biological activities.
- The biopharmaceutical market sector is growing faster than pharmaceuticals overall and is set to represent 15% to 25% of all pharmaceuticals within five years, generating global sales in excess of US$200 billion by 2020.
